85373-96-2

Usage

Uses

Used in Organic Synthesis:
2-Bromo-4-carboxy-alpha,alpha,alpha-trifluoroanisole is used as a reagent in the synthesis of various organic compounds, leveraging its unique reactivity to facilitate the formation of complex molecules.
Used in Pharmaceutical Production:
In the pharmaceutical industry, 2-Bromo-4-carboxy-alpha,alpha,alpha-trifluoroanisole serves as an intermediate, contributing to the development of new drugs by providing a key structural component in their synthesis.
Used in Agrochemical Production:
Similarly, in agrochemicals, 2-Bromo-4-carboxy-alpha,alpha,alpha-trifluoroanisole is utilized as an intermediate, playing a crucial role in the synthesis of effective and targeted crop protection agents.
2-Bromo-4-carboxy-alpha,alpha,alpha-trifluoroanisole's reactivity and properties make it a valuable asset in the field of organic chemistry and chemical synthesis, with its applications spanning across different industries to create innovative and effective products.

Upstream product

• 330-12-1 4-trifluoromethoxybenzoic acid 
• 85366-66-1 3-bromo-4-(trifluoromethoxy)benzaldehyde 
• 656-06-4 3-amino-4-(trifluoromethoxy)benzoic acid 

Downstream Products

• 929891-53-2 3-bromo-N-(4-morpholin-4-ylphenyl)-4-trifluoromethoxy-benzamide 
• 1174512-65-2 3-cyano-4-(trifluoromethoxy)benzoic acid 
• 1131594-45-0 methyl 3-bromo-4-(trifluoromethoxy)benzoate 

Relevant academic research and scientific papers

SUBSTITUTED 1,2,3,4- TETRAHYDROCYCLOPENTA[b]INDOL-3-YL) ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS

The present invention relates to certain substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives of Formula (Ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1 receptor-associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, microbial infections or diseases and viral infections or diseases.

PIPERAZINE METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLUR5) NEGATIVE ALLOSTERIC MODULATORS FOR ANXIETY/DEPRESSION

The present teachings relate to piperazine metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulators having Formula (I); wherein the constituent variables are as defined herein. The present teachings further relate to methods for the preparation of the compounds, and to methods for using the compounds for treatment of diseases and disorders including schizophrenia, paranoia, depression, manic-depressive illness and anxiety.

DIHYDRO- 1H- PYRROLO [1,2-A] INDOL-1-YL CARBOXYLIC DERIVATIVES WHICH ACT AS S1P1 AGONISTS

The present invention relates to certain (1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl carboxylic acid derivatives of Formula (Ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1 associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, sepsis, myocardial infarction, ischemic stroke, acne, microbial infections or diseases and viral infections or diseases.

BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C

A compound which is a biphenyl derivative of formula (I), or a pharmaceutically acceptable salt thereof wherein: R1 is a C1-C6 alkyl group or a moiety -A1, -L1-A1, -A1-A1′, -L1-A1-A1′, -A1-L1-A1′, -A1-Y1-A1′, -A1-Het1-A1′, -L1-A1-Y1-A1′, -L1-A1-Het1-A1′, -L1-Het1-A1, -L1-Y1-A1, -L1-Y1-Het1-A1, -L1-Het1-Y1-A1, -L1-Y1-Het1-L1′, -A1-Y1-Het1-A1′, -A1-Het1-Y1-A1′, -A1-Het1-L1-A1′, -A1-L1-Het1-A1′ or -L1-Het1-L1′; - A and B are the same or different and each represent a direct bond or a -CO- NR′-, -NR′-CO-, -NR′-CO2-, -CO-, -NR′-CO-NR′′-, -NR′-S(O)2-, -S(O)2-NR′-, -SO2-, -NR′-, -NR′-CO-CO-, -CO-O-, -O-CO-, -(C1-C2 alkylene)-NR′- or -(C1-C2 hydroxyalkylene)-NR′ - moiety, wherein R′ and R′′ are the same or different and each represent hydrogen or C1-C4 alkyl; - R2 and R3 are the same or different and each represent C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy or halogen; n and m are the same or different and each represent 0 or 1 ; R4 is a C1-C6 alkyl group or a moiety -A4, -L4-A4, -A4-A4′, -L4-A4-A4′ , -A4-L4-A4′, -A4-Y4-A4′, -A4-Het4-A4′, -L4-A4-Y4-A4′, -L4-A4-Het4-A4′, -L4-Het4-A4, -L4-Y4-A4, -L4-Y4-Het4-A4, -L4-Het4-Y4-A4, -L4-Y4-Het4-L4′, -A4-Y4-Het4-A4′, -A4-Het4-Y4-A4′, -A4-Het4-L4-A4′, -A4-L4-Het4-A4′ or -L4-Het4-L4′, each A1, A4, A1′ and A4′ are the same or different and represent a phenyl, 5- to 10- membered heteroaryl, 5- to 10- membered heterocyclyl or C3-C8 carbocyclyl moiety; each L1 and L4 is the same or different and represents a C1-C4 alkylene or a C1-C4 hydroxyalkylene group; each Y1 and Y4 is the same or different and represents -CO-, -SO- or -S(O)2-; each L1′ and L4′ is the same or different and represents hydrogen or a C1-C4 alkyl group; and each Het1 and Het4 is the same or different and represents -O-, -S- or -NR′-, wherein R′ is hydrogen or a C1-C4 alkyl group, the phenyl, heteroaryl, heterocyclyl and carbocyclyl moieties in R1 and R4 being optionally fused to a phenyl, 5- to 10- membered heteroaryl or 5- to 10- membered heterocyclyl ring; and the phenyl, heteroaryl, heterocyclyl and carbocyclyl moieties in R1 and R4 being unsubstituted or substituted by (a) a single unsubstituted substituent selected from -(C1-C4 alkyl)-X1, -CO2R′, -SO2NR′R′′, -S(O)2-R′, -CONR′R′′, -NR′-CO-R′′′, -NR′-S(O)2-R′′′, -CO-NR′-(C1-C4 alkyl)-NR′R′′ and -CO-O-(C1-C4 alkyl)-NR′R′′ and/or (b) 1, 2 or 3 unsubstituted substituents selected from -(C1-C4 alkyl)-X2, halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 hydroxyalkyl, hydroxy, cyano, nitro and -NR′R′′, wherein X1 is -CO2R′, -SO2-R′, -NR′-CO2-R′′, -NR′-S(O)2-R′′′, -CONR′R′′ or -SO2-NR′R′′, each X2 is the same or different and is cyano, nitro or -NR′R′′, each R′ and R′′ is the same or different and represents hydrogen or C1-C4 alkyl and each R′′′ is the same or different and represents C1-C4 alkyl.